PT3930715T - Saracatinib para uso no tratamento de fibrose pulmonar idiopática - Google Patents
Saracatinib para uso no tratamento de fibrose pulmonar idiopáticaInfo
- Publication number
- PT3930715T PT3930715T PT207106071T PT20710607T PT3930715T PT 3930715 T PT3930715 T PT 3930715T PT 207106071 T PT207106071 T PT 207106071T PT 20710607 T PT20710607 T PT 20710607T PT 3930715 T PT3930715 T PT 3930715T
- Authority
- PT
- Portugal
- Prior art keywords
- saracatinib
- treatment
- pulmonary fibrosis
- idiopathic pulmonary
- idiopathic
- Prior art date
Links
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 title 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 title 1
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 title 1
- 229950009919 saracatinib Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962811009P | 2019-02-27 | 2019-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3930715T true PT3930715T (pt) | 2024-08-02 |
Family
ID=69784492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT207106071T PT3930715T (pt) | 2019-02-27 | 2020-02-26 | Saracatinib para uso no tratamento de fibrose pulmonar idiopática |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220117966A1 (https=) |
| EP (1) | EP3930715B1 (https=) |
| JP (2) | JP7547356B2 (https=) |
| CN (1) | CN113811296B (https=) |
| DK (1) | DK3930715T3 (https=) |
| ES (1) | ES2994095T3 (https=) |
| FI (1) | FI3930715T3 (https=) |
| HU (1) | HUE067967T2 (https=) |
| MA (1) | MA55076A (https=) |
| PT (1) | PT3930715T (https=) |
| TW (1) | TWI836022B (https=) |
| WO (1) | WO2020174420A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112674031B (zh) * | 2020-12-03 | 2021-11-30 | 同济大学 | 新型冠状病毒感染的啮齿动物模型的构建方法和用途 |
| US20250161250A1 (en) * | 2022-02-28 | 2025-05-22 | Nuformix Technologies Limited | Compositions and methods for treatment of idiopathic pulmonary fibrosis |
| CN117618436A (zh) * | 2022-08-25 | 2024-03-01 | 广州再极医药科技有限公司 | 一种稠环嘧啶类化合物的用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| GB0427697D0 (en) | 2004-12-17 | 2005-01-19 | Astrazeneca Ab | Chemical process |
| US9844528B2 (en) * | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| CN102675282B (zh) * | 2011-03-15 | 2014-12-24 | 广东东阳光药业有限公司 | 取代的喹啉化合物及其使用方法和用途 |
| US20130336889A1 (en) * | 2012-06-14 | 2013-12-19 | National Taiwan University | Nanoparticle and method for detecting or treating a tumor using the same |
| CN105294682B (zh) * | 2014-07-26 | 2017-07-07 | 广东东阳光药业有限公司 | Cdk类小分子抑制剂的化合物及其用途 |
| EP4653015A3 (en) * | 2015-01-26 | 2025-12-31 | Yale University | COMPOSITIONS AND METHODS OF USE OF TYROSINE KINASE INHIBITORS |
| EP3277282B1 (en) * | 2015-04-01 | 2022-10-12 | Istanbul Universitesi Rektorlugu | Dasatinib for use in the treatment, regression or decelerating the progress of fibrotic lung diseases |
| GB201514760D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| JP6905662B2 (ja) * | 2015-11-14 | 2021-07-21 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | 置換キノリン化合物の結晶形およびその医薬組成物 |
| EP3228630A1 (en) * | 2016-04-07 | 2017-10-11 | IMBA-Institut für Molekulare Biotechnologie GmbH | Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer |
| WO2018026441A1 (en) * | 2016-08-01 | 2018-02-08 | The Regents Of The University Of California | Methods for preventing or treating fibrotic diseases |
| WO2018046876A1 (en) * | 2016-09-06 | 2018-03-15 | The University Of Birmingham | Treatment of chronic inflammatory disease |
| CN106692150B (zh) * | 2016-12-21 | 2019-08-20 | 中国人民解放军第三〇二医院 | 尼达尼布在制备预防和治疗肝纤维化与肝硬化的药物中的用途 |
| EP3964214A1 (en) * | 2020-09-02 | 2022-03-09 | Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. | Modulators of airway basal cells for the treatment or prevention of lung diseases |
-
2020
- 2020-02-26 EP EP20710607.1A patent/EP3930715B1/en active Active
- 2020-02-26 ES ES20710607T patent/ES2994095T3/es active Active
- 2020-02-26 CN CN202080016378.4A patent/CN113811296B/zh active Active
- 2020-02-26 WO PCT/IB2020/051642 patent/WO2020174420A1/en not_active Ceased
- 2020-02-26 JP JP2021550035A patent/JP7547356B2/ja active Active
- 2020-02-26 DK DK20710607.1T patent/DK3930715T3/da active
- 2020-02-26 PT PT207106071T patent/PT3930715T/pt unknown
- 2020-02-26 MA MA055076A patent/MA55076A/fr unknown
- 2020-02-26 HU HUE20710607A patent/HUE067967T2/hu unknown
- 2020-02-26 FI FIEP20710607.1T patent/FI3930715T3/fi active
- 2020-02-26 US US17/434,036 patent/US20220117966A1/en active Pending
- 2020-02-27 TW TW109106616A patent/TWI836022B/zh active
-
2024
- 2024-08-28 JP JP2024146122A patent/JP2024174909A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113811296A (zh) | 2021-12-17 |
| ES2994095T3 (en) | 2025-01-17 |
| MA55076A (fr) | 2022-04-20 |
| DK3930715T3 (da) | 2024-08-05 |
| TWI836022B (zh) | 2024-03-21 |
| EP3930715B1 (en) | 2024-05-08 |
| HUE067967T2 (hu) | 2024-12-28 |
| JP2024174909A (ja) | 2024-12-17 |
| FI3930715T3 (fi) | 2024-08-05 |
| CN113811296B (zh) | 2025-05-16 |
| EP3930715A1 (en) | 2022-01-05 |
| JP2022521635A (ja) | 2022-04-11 |
| JP7547356B2 (ja) | 2024-09-09 |
| WO2020174420A1 (en) | 2020-09-03 |
| TW202045180A (zh) | 2020-12-16 |
| US20220117966A1 (en) | 2022-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002043A1 (es) | Métodos y composiciones para la entrega de proteínas terapeuticas. | |
| IL282487A (en) | Tyk2 inhibitors and uses thereof | |
| PT3858333T (pt) | Preparação e armazenamento de formulações de arn lipossómico adequadas para terapia | |
| IL289553A (en) | Pyrrolo[2,3-b]pyrazines as hpk1 inhibitor and the use thereof | |
| IL286248A (en) | Tyk2 inhibitors and uses thereof | |
| BR112016025910A2 (pt) | uso de uma quantidade eficaz de glyx-13, uso de glyx-13 e um antagonista de nmdar e composição farmaceuticamente aceitável compreendendo os mesmos | |
| IL277694A (en) | Pharmacologically active history of pyrazolo-trizine and/or pyrazolo-pyrimidine | |
| BR112017026209A2 (pt) | fragmentos e variantes de endostatinas para uso no tratamento de fibrose | |
| PT3930715T (pt) | Saracatinib para uso no tratamento de fibrose pulmonar idiopática | |
| PL4076652T3 (pl) | Farmaceutycznie dopuszczalna sól atrasentanu do zastosowania w sposobie leczenia nefropatii iga | |
| IL280770A (en) | Diazabicyclooctanones as inhibitors of serine beta-lactamases | |
| BR112016014253A2 (pt) | Métodos para acabamento de fibras e/ou tecidos e para determinação quantitativa do acúmulo de microrganismos em um substrato sólido, e, uso de um derivado de silano hidrofílicos | |
| IL288871A (en) | Novel non-coding heterocyclic amino acids (nchaa) and their use as herbicides | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| EP3847924C0 (en) | FIVE-IN-ONE POLISHING HEAD | |
| FI3724196T3 (fi) | Substituoituja atsetidiinidihydrotienopyridiinejä ja niiden käyttö fosfodiesteraasin estäjinä | |
| BR112018001942A2 (pt) | ?novo uso de sulfato de dextrano? | |
| BR112018006560A2 (pt) | composições para higiene bucal e métodos de uso das composições. | |
| CL2020001339A1 (es) | Composiciones y métodos de uso para tratar la inflamación aberrante en las glándulas secretoras peri-oculares o en la superficie ocular. | |
| IL287560A (en) | Mrna formulation | |
| IL285047A (en) | Cell-specific transcriptional regulatory sequences and uses thereof | |
| EP3923938C0 (en) | IFENPRODIL OR RADIPRODIL FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | |
| CL2021002512A1 (es) | Formulaciones liposomales y métodos para usar y preparar las mismas. | |
| PL3320901T3 (pl) | Dimetyloaminomicheliolid do zastosowania w leczeniu włóknienia płuc | |
| EP3782647A4 (en) | ANTI-FIBROTIC AGENT AND BIOMARKER OF FIBROSIS |